Compare ESLA & HKIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLA | HKIT |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 28.3M |
| IPO Year | 2021 | 2018 |
| Metric | ESLA | HKIT |
|---|---|---|
| Price | $0.73 | $2.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 23.6K | ★ 41.0K |
| Earning Date | 05-26-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.03 |
| 52 Week High | $3.15 | $8.80 |
| Indicator | ESLA | HKIT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.44 |
| Support Level | N/A | $2.84 |
| Resistance Level | N/A | $3.59 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 43.37 |
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.